| Personalized Medicine 2010 | | | | * Regulatory and legal issues surrounding |
| | | | | personalized medicine |
| The era of Personalized Medicine is set to | | | | * Payer reimbursement challenges |
| revolutionize the healthcare industry. As our | | | | * Marketing strategies to capitalize profits |
| knowledge of genetics and molecular biology rapidly | | | | * Survey results from key opinion leaders across |
| expands, a personalized approach to medical care is | | | | the life sciences industry |
| becoming increasingly important. Not only does this | | | | |
| paradigm promise to improve an individual's treatment | | | | Key questions answered Personalized Medicine 2010 |
| outcome and reduce healthcare expenditure, | | | | include: |
| personalized medicine is set to transform the | | | | |
| pharmaceutical/biotechnology and companion | | | | * What are the major challenges in this market and |
| diagnostic markets. ( ) | | | | how can these be overcome? |
| | | | | * How will pharmacogenomics transform clinical |
| Personalized Medicine 2010 report provides an | | | | trials? |
| in-depth assessment of this burgeoning market, and | | | | * What are the leading pharmacogenomic products |
| examines the major challenges that need to be | | | | on the market? |
| overcome to maximize success. | | | | * Who are the key players involved in the market |
| | | | | and what strategies are they using to enhance |
| Key features of Personalized Medicine 2010 include: | | | | product performance? |
| | | | | * What pharmaceutical/biotechnology and diagnostic |
| * Case studies of leading pharmacogenomic | | | | companies are seeking alliances in 2010? |
| products | | | | * How can company alliances maximize commercial |
| * Analysis of the personalized medicine market, | | | | success? |
| including seven major market sales forecasts to 2016 | | | | |